Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials

Tenório, Marilene Brandão; Ferreira, Raphaela Costa; Moura, Fabiana Andréa; Bueno, Nassib Bezerra; Goulart, Marília Oliveira Fonseca; Oliveira, Alane Cabral Menezes de

doi:10.1016/j.numecd.2018.06.002

Cited by 68 publications

(45 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single trial in which CoQ 10 has been assumed at the dose of 200 mg/day for 20 weeks until delivery concluded with a reduction of the risk of developing pre-eclampsia in women at risk for the condition (p = 0.035) [165]. However, a recent meta-analysis of twenty-nine RCTs highlighted that the antioxidant strategy, both by using of CoQ 10 and by using of other agents (vitamins, resveratrol, or/and arginine), did not exert significant beneficial effects on maternal and fetal outcomes [166]. Further research is needed in this field.…”

Section: Pre-eclampsiamentioning

confidence: 99%

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

Coenzyme Q10 (CoQ10) is a ubiquitous factor present in cell membranes and mitochondria, both in its reduced (ubiquinol) and oxidized (ubiquinone) forms. Its levels are high in organs with high metabolism such as the heart, kidneys, and liver because it acts as an energy transfer molecule but could be reduced by aging, genetic factors, drugs (e.g., statins), cardiovascular (CV) diseases, degenerative muscle disorders, and neurodegenerative diseases. As CoQ10 is endowed with significant antioxidant and anti-inflammatory features, useful to prevent free radical-induced damage and inflammatory signaling pathway activation, its depletion results in exacerbation of inflammatory processes. Therefore, exogenous CoQ10 supplementation might be useful as an adjuvant in the treatment of cardiovascular diseases such as heart failure, atrial fibrillation, and myocardial infarction and in associated risk factors such as hypertension, insulin resistance, dyslipidemias, and obesity. This review aims to summarize the current evidences on the use of CoQ10 supplementation as a therapeutic approach in cardiovascular diseases through the analysis of its clinical impact on patients’ health and quality of life. A substantial reduction of inflammatory and oxidative stress markers has been observed in several randomized clinical trials (RCTs) focused on several of the abovementioned diseases, even if more RCTs, involving a larger number of patients, will be necessary to strengthen these interesting findings.

show abstract

Section: Pre-eclampsiamentioning

confidence: 99%

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In an experimental study in the reduced uterine perfusion pressure model for PE in Sprague-Dawley rats, N-acetylcysteine reduced blood pressure without adversely effecting fetal weight [88]. However, according to a number of studies [89,90] and meta-analysis of randomized controlled trials [118] antioxidant therapy with N-acetylcysteine ameliorated the severity of oxidative stress in pre-eclampsia but had no effects for prevention of PE. Administration of dexmedetomidine, a sedative affecting the α2 adrenaline receptor, which is commonly used in intensive care, has been shown to improve survival and to preserve eGC in a rat heatstroke model [119].…”

Section: Metforminmentioning

confidence: 99%

Can Endothelial Glycocalyx Be a Major Morphological Substrate in Pre-Eclampsia?

Ziganshina

Yarotskaya

Bovin

et al. 2020

IJMS

View full text Add to dashboard Cite

Today pre-eclampsia (PE) is considered as a disease of various theories; still all of them agree that endothelial dysfunction is the leading pathogenic factor. Endothelial dysfunction is a sequence of permanent immune activation, resulting in the change of both the phenotype and the functions of an endothelial cell and of the extracellular layer associated with the cell membrane—endothelial glycocalyx (eGC). Numerous studies demonstrate that eGC mediates and regulates the key functions of endothelial cells including regulation of vascular tone and thromboresistance; and these functions are disrupted during PE. Taking into account that eGC and its components undergo alterations under pathological conditions leading to endothelial activation, it is supposed that eGC plays a certain role in pathogenesis of PE. Envisaging the eGC damage as a key factor of PE, might be a new approach to prevention, treatment, and rehabilitation of patients with PE. This approach could include the development of drugs protecting eGC and promoting regeneration of this structure. Since the issue of PE is far from being solved, any effort in this direction might be valuable.

show abstract

“…Resveratrol reduces the risk of thrombosis in experimental liver cirrhosis, normalizing platelet function (Xu et al 2016). Resveratrol has pronounced positive effects in preeclampsia in humans and in experiment (Tenório et al 2018, Bariani et al 2017, Ivanets et al 2015. The ability of resveratrol under experimental conditions to reduce inflammation induced by lipopolysaccharides, and to prevent preterm labor was found in (Bariani et al 2017).…”

Section: Resultsmentioning

confidence: 99%

L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil

Ступакова¹,

Лазарева²,

Гуреев³

et al. 2019

RRP

View full text Add to dashboard Cite

Introduction. Preeclampsia is a formidable disease of the second half of pregnancy, leading to severe complications, including disability and even death. Many authors have recognized the correlation between the severity of preeclampsia and the degree of disturbances in the hemostasis system. In this regard, the objective of this study was to assess inhibition of platelet aggregation and the possibility of its correction with resverаtrol and nicorandil. Materials and methods. The study was performed on 250 mature white Wistar female rats weighing 250–300 g. The platelet aggregation induced by ADP, collagen, ristomycin, adrenaline was determined, as well as PTT, TT, aPTT, fibrinogen, and the clotting time. Results and discussion. Introduction of resverаtrol and nicorandil resulted in a decrease in thrombocyte aggregation capacity from 53.8 ± 2.60% to 22.1 ± 1.25% and 37.1 ± 1.79%, respectively, when using ADP as an inducer. The clotting time was from 841 ± 42 s up to 1135 ± 33 s and 1034 ± 26 s, respectively. In addition, there was an increase in temporal parameters of plasma-coagulation hemostasis and a decrease in plasma fibrinogen content. The use of glibenclamide resulted in partial cancellation of the positive effects of resverаtrol and nicorandil, with an increase in platelet aggregation to 28.9 ± 1.8% and 43.9 ± 1.2% when using ADP as an inducer and a decrease in the thrombosis time to 988 ± 26 s and 950 ± 22 s, respectively. Conclusion. In animals with experimental preeclampsia, there were disturbances in the hemostasis system, comparable to those in the clinical situation. The use of resverаtrol and nicorandil leads to a pronounced correction of hemostasis parameters. The positive effects of the studied pharmacological agents are mediated by several mechanisms, including K+ATP channels.

show abstract

Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials

Cited by 68 publications

References 40 publications

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

Coenzyme Q10: Clinical Applications in Cardiovascular Diseases

Can Endothelial Glycocalyx Be a Major Morphological Substrate in Pre-Eclampsia?

L-NAME-induced Preeclampsia: correction of functional disorders of the hemostasis system with Resveratrol and Nicorandil

Contact Info

Product

Resources

About